Verastem
Verastem Oncology RAF/MEKFocus

Research

Verastem Oncology’s research portfolio consists of novel small molecule drugs that seek to treat cancer by inhibiting critical signaling pathways that promote cancer cell survival and tumor growth.

Our programs target RAF/MEK inhibition, focal adhesion kinase (FAK), and phosphoinositide 3-kinase (PI3K-delta/gamma). Preclinical research has shown that these targets are important for both cancer cell survival and the tumor microenvironment that supports the cancer cells.